Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
出版年份 2016 全文链接
标题
Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 15, Pages 4158-4163
出版商
Proceedings of the National Academy of Sciences
发表日期
2016-03-29
DOI
10.1073/pnas.1601649113
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics
- (2015) Jennifer A. Afranie-Sakyi et al. CANCER LETTERS
- VEGF-A/VEGFR Inhibition Restores Hematopoietic Homeostasis in the Bone Marrow and Attenuates Tumor Growth
- (2015) R. K. O'Donnell et al. CANCER RESEARCH
- Vascular endothelial growth factor-dependent angiogenesis and dynamic vascular plasticity in the sensory circumventricular organs of adult mouse brain
- (2015) Shoko Morita et al. CELL AND TISSUE RESEARCH
- VEGF-B-Neuropilin-1 signaling is spatiotemporally indispensable for vascular and neuronal development in zebrafish
- (2015) Lasse D. Jensen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGF-VEGFR Signals in Health and Disease
- (2014) Masabumi Shibuya Biomolecules & Therapeutics
- Systemic safety of anti-VEGF drugs: a commentary
- (2014) Lauren J Scott et al. Expert Opinion On Drug Safety
- VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
- (2014) Yihai Cao Nature Reviews Endocrinology
- Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues
- (2014) J. Honek et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization
- (2014) Sharon Lim et al. Cell Reports
- Liver sinusoidal endothelial cells and liver regeneration
- (2013) Laurie D. DeLeve JOURNAL OF CLINICAL INVESTIGATION
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth
- (2013) Xiaojuan Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
- (2013) Y. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
- (2012) Jennifer A. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Changing End Points in Breast-Cancer Drug Approval — The Avastin Story
- (2011) Ralph B. D'Agostino NEW ENGLAND JOURNAL OF MEDICINE
- Forty-Year Journey of Angiogenesis Translational Research
- (2011) Y. Cao et al. Science Translational Medicine
- A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models
- (2010) Yanlan Yu et al. PLoS One
- Vascular Endothelial Growth Factor
- (2009) Napoleone Ferrara ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly – A Mini-Review
- (2009) S. Boehm et al. GERONTOLOGY
- The nuances of therapy
- (2009) Lee M. Ellis et al. NATURE
- Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
- (2009) Y. Cao Science Signaling
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started